Project Grant R43HL178322
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $228K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $1.775 million to Boston Children's Hospital on September 1, 2026, to investigate pericyte-to-smooth-muscle-cell transitions in pulmonary arterial hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses excessive vascular remodeling in pulmonary arterial hypertension by examining how pericytes—specialized mural cells that maintain capillary stability—transition into smooth muscle-like cells under...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $516,181 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective observational ancillary study nested within the MIDAS (Milrinone for Prevention of Post-Ligation Cardiac Syndrome) clinical trial. The study uses non-invasive bedside monitoring techniques—near-infrared spectroscopy (NIRS), lung ultrasound (LUS), and targeted neonatal echocardiography...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Carnegie Mellon University $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect lung spatial-biological niches in early fibrogenesis. The research project aims to spatially profile and recapitulate disease-specific microenvironments that drive early fibrogenesis in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis. The work addresses a clinical need to elucidate...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $779,600 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the developmental mechanisms that direct cardiac cell diversification and left ventricle morphogenesis. The research employs single-cell transcriptomic analyses and lineage tracing in mouse embryos to define the gene regulatory networks controlling how diverse cardiac cell types emerge from...
- The National Heart, Lung, and Blood Institute (NHLBI) at the Department of Health and Human Services awarded The Leland Stanford Junior University $755,271 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop, validate, and clinically evaluate a magnetic resonance imaging method for assessing blood flow hemodynamics in pediatric and young adult congenital heart disease patients. The project will augment 4D-flow MRI capabilities to enable direct...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Leland Stanford Junior University $165,888 on April 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for Project Grant K08HL183852 to investigate T cell contributions to neointima formation in pulmonary hypertension. The research examines how proliferating T cell lineages and their expressed ligands drive neointimal lesion development in pulmonary hypertension, a fatal disease...
- The National Heart, Lung, and Blood Institute awarded Starlight Cardiovascular, Inc. $499,952 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, to advance commercialization of a catheter-delivered, adjustable percutaneous pulmonary flow restrictor designed to replace surgical pulmonary artery banding in newborns with hypoplastic left heart syndrome and other congenital heart defects. The flow restrictor addresses clinical limitations of current surgical...